Glecaprevir 是一种新型的 HCV NS3/4A 蛋白酶 (HCV NS3/4A protease) 抑制剂，其 IC₅₀ 值在 3.5 和 11.3 nM 之间。Glecaprevir 也是 SARS-CoV 3CL^pro 的抑制剂，IC₅₀ 为 4.09 μM。

Glecaprevir is a novel HCV NS3/4A protease inhibitor, with IC 50 values ranging from 3.5 to 11.3 nM. Glecaprevir is also a SARS-CoV 3CL inhibitor with an IC 50 of 4.09 μM.

Solid

IC50: 3.5~11.3 nM (HCV NS3/4A protease)

Glecaprevir inhibits the enzymatic activity of HCV genotype 1-6 NS3/4A proteases with half maximal inhibitory concentration (IC50) values ranging from 3.5 to 11.3 nM in a biochemical assay. Glecaprevir inhibites HCV subgenomic stable replicons containing proteases from HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, 6a and 6e in Huh-7 cells with 50% effective concentration (EC50) values ranging from 0.21 to 4.6 nM. Glecaprevir is active against a replicon containing protease from genotype 3, the most difficult-to-treat HCV genotype, with an EC50 value of 1.9 nM, which is 10- and 44-fold lower than those for paritaprevir and grazoprevir, respectively. The median Glecaprevir EC50 values against replicons containing these genotype 1a, 1b, 2a, 2b, 3a, 4a, 4d, and 5a clinical samples are 0.08, 0.29, 1.6, 2.2, 2.3, 0.41, 0.17, and 0.12 nM, respe

Room temperature in continental US; may vary elsewhere.

Powder -20°C 3 years；4°C 2 years

[1]. Ng TI, et al. In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir. Antimicrob Agents Chemother. 2017 Oct 30. pii: AAC.01620-17.
[2]. Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6(1):212.

In Vitro: DMSO : ≥ 83.3 mg/mL (99.30 mM)配制储备液